Parallax Volatility Advisers’s Atara Biotherapeutics ATRA Stock Holding History

Parallax Volatility Advisers’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4	Closed	-$2K	–	2316
2019 Q2	$2K	Buy	+4	New	+$2.82K	﹤0.01%	2365
2018 Q3	–	Sell	-12	Closed	-$11K	–	2565
2018 Q2	$11K	Buy	+12	New	+$12.9K	﹤0.01%	1733
2018 Q1	–	Sell	-158	Closed	-$71K	–	2257
2017 Q4	$71K	Buy	+158	New	+$58.3K	﹤0.01%	3006
2016 Q1	–	Sell	-470	Closed	-$311K	–	2476
2015 Q4	$311K	Buy	+470	New	+$356K	﹤0.01%	1720

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Parallax Volatility Advisers's ATRA Position: Q3 2019 in Review

Parallax Volatility Advisers sold out of Atara Biotherapeutics (ATRA) in Q3 2019, closing a stake of 4 shares — an estimated $2K sold.

Parallax Volatility Advisers first reported a position in ATRA in Q4 2015 and held it in 4 quarters. The position peaked at $311K in Q4 2015. 112 funds tracked by Wall St. Rank hold ATRA as of Q3 2019.

Parallax Volatility Advisers reported no remaining Atara Biotherapeutics position as of Q3 2019 after selling out during the quarter.
Parallax Volatility Advisers sold 4 Atara Biotherapeutics shares in Q3 2019, an estimated $2K.
Parallax Volatility Advisers first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 4 quarters.
Parallax Volatility Advisers's Atara Biotherapeutics position peaked at $311K in Q4 2015.
112 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2019.

Based on Parallax Volatility Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.